Summary

Naltrexone Market – Scope of Report
TMR’s report on the global naltrexone market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global naltrexone market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global naltrexone market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the naltrexone market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global naltrexone market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global naltrexone market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global naltrexone market.

The report delves into the competitive landscape of the global naltrexone market. Key players operating in the global naltrexone market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global naltrexone market profiled in this report.

Key Questions Answered in Global naltrexone Market Report
• What is the sales/revenue generated by naltrexone across all regions during the forecast period?
• What are the opportunities in the global naltrexone market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Naltrexone Market – Research Objectives and Research Approach
The comprehensive report on the global naltrexone market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global naltrexone market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global naltrexone market.

ページTOPに戻る

Table of Contents

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Naltrexone Market
4. Market Overview
    4.1. Introduction
        4.1.1. Product Definition
        4.1.2. Industry Evolution/Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Naltrexone Market Analysis and Forecast, 2020-2034
5. Key Insights
    5.1. Pipeline Analysis
    5.2. Key Product /Brand Analysis
    5.3. Key Mergers & Acquisitions
    5.4. COVID-19 Pandemic Impact on Industry
6. Global Naltrexone Market Analysis and Forecast, by Type
    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Type, 2020-2034
        6.3.1. 25 mg
        6.3.2. 50 mg
    6.4. Market Attractiveness Analysis, by Type
7. Global Naltrexone Market Analysis and Forecast, by Application
    7.1. Introduction & Definition
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Application, 2020-2034
        7.3.1. Opioid Independence
        7.3.2. Alcohol Independence
    7.4. Market Attractiveness Analysis, by Application
8. Global Naltrexone Market Analysis and Forecast, by End-user
    8.1. Introduction & Definition
    8.2. Key Findings/Developments
    8.3. Market Value Forecast, by End-user, 2020-2034
        8.3.1. Hospitals & Clinics
        8.3.2. Rehabilitation Centers
        8.3.3. Wellness Centers
        8.3.4. Others (Research and Academic Institutes, etc.)
    8.4. Market Attractiveness Analysis, by End-user
9. Global Naltrexone Market Analysis and Forecast, by Region
    9.1. Key Findings
    9.2. Market Value Forecast, by Region, 2020-2034
        9.2.1. North America
        9.2.2. Europe
        9.2.3. Asia Pacific
        9.2.4. Latin America
        9.2.5. Middle East & Africa
    9.3. Market Attractiveness Analysis, by Region
10. North America Naltrexone Market Analysis and Forecast
    10.1. Introduction
    10.2. Key Findings
    10.3. Market Value Forecast, by Type, 2020-2034
        10.3.1. 25 mg
        10.3.2. 50 mg
    10.4. Market Value Forecast, by Application, 2020-2034
        10.4.1. Opioid Independence
        10.4.2. Alcohol Independence
    10.5. Market Value Forecast, by End-user, 2020-2034
        10.5.1. Hospitals & Clinics
        10.5.2. Rehabilitation Centers
        10.5.3. Wellness Centers
        10.5.4. Others (Research and Academic Institutes, etc.)
    10.6. Market Value Forecast, by Country, 2020-2034
        10.6.1. U.S.
        10.6.2. Canada
    10.7. Market Attractiveness Analysis
        10.7.1. By Type
        10.7.2. By Application
        10.7.3. By End-user
        10.7.4. By Country
11. Europe Naltrexone Market Analysis and Forecast
    11.1. Introduction
    11.2. Key Findings
    11.3. Market Value Forecast, by Type, 2020-2034
        11.3.1. 25 mg
        11.3.2. 50 mg
    11.4. Market Value Forecast, by Application, 2020-2034
        11.4.1. Opioid Independence
        11.4.2. Alcohol Independence
    11.5. Market Value Forecast, by End-user, 2020-2034
        11.5.1. Hospitals & Clinics
        11.5.2. Rehabilitation Centers
        11.5.3. Wellness Centers
        11.5.4. Others (Research and Academic Institutes, etc.)
    11.6. Market Value Forecast, by Country/Sub-region, 2020-2034
        11.6.1. Germany
        11.6.2. U.K.
        11.6.3. France
        11.6.4. Italy
        11.6.5. Spain
        11.6.6. Rest of Europe
    11.7. Market Attractiveness Analysis
        11.7.1. By Type
        11.7.2. By Application
        11.7.3. By End-user
        11.7.4. By Country/Sub-region
12. Asia Pacific Naltrexone Market Analysis and Forecast
    12.1. Introduction
    12.2. Key Findings
    12.3. Market Value Forecast, by Type, 2020-2034
        12.3.1. 25 mg
        12.3.2. 50 mg
    12.4. Market Value Forecast, by Application, 2020-2034
        12.4.1. Opioid Independence
        12.4.2. Alcohol Independence
    12.5. Market Value Forecast, by End-user, 2020-2034
        12.5.1. Hospitals & Clinics
        12.5.2. Rehabilitation Centers
        12.5.3. Wellness Centers
        12.5.4. Others (Research and Academic Institutes, etc.)
    12.6. Market Value Forecast, by Country/Sub-region, 2020-2034
        12.6.1. China
        12.6.2. Japan
        12.6.3. India
        12.6.4. Australia & New Zealand
        12.6.5. Rest of Asia Pacific
    12.7. Market Attractiveness Analysis
        12.7.1. By Type
        12.7.2. By Application
        12.7.3. By End-user
        12.7.4. By Country/Sub-region
13. Latin America Naltrexone Market Analysis and Forecast
    13.1. Introduction
    13.2. Key Findings
    13.3. Market Value Forecast, by Type, 2020-2034
        13.3.1. 25 mg
        13.3.2. 50 mg
    13.4. Market Value Forecast, by Application, 2020-2034
        13.4.1. Opioid Independence
        13.4.2. Alcohol Independence
    13.5. Market Value Forecast, by End-user, 2020-2034
        13.5.1. Hospitals & Clinics
        13.5.2. Rehabilitation Centers
        13.5.3. Wellness Centers
        13.5.4. Others (Research and Academic Institutes, etc.)
    13.6. Market Value Forecast, by Country/Sub-region, 2020-2034
        13.6.1. Brazil
        13.6.2. Mexico
        13.6.3. Rest of Latin America
    13.7. Market Attractiveness Analysis
        13.7.1. By Type
        13.7.2. By Application
        13.7.3. By End-user
        13.7.4. By Country/Sub-region
14. Middle East & Africa Naltrexone Market Analysis and Forecast
    14.1. Introduction
    14.2. Key Findings
    14.3. Market Value Forecast, by Type, 2020-2034
        14.3.1. 25 mg
        14.3.2. 50 mg
    14.4. Market Value Forecast, by Application, 2020-2034
        14.4.1. Opioid Independence
        14.4.2. Alcohol Independence
    14.5. Market Value Forecast, by End-user, 2020-2034
        14.5.1. Hospitals & Clinics
        14.5.2. Rehabilitation Centers
        14.5.3. Wellness Centers
        14.5.4. Others (Research and Academic Institutes, etc.)
    14.6. Market Value Forecast, by Country/Sub-region, 2020-2034
        14.6.1. GCC Countries
        14.6.2. South Africa
        14.6.3. Rest of Middle East & Africa
    14.7. Market Attractiveness Analysis
        14.7.1. By Type
        14.7.2. By Application
        14.7.3. By End-user
        14.7.4. By Country/Sub-region
15. Competition Landscape
    15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
    15.2. Market Share Analysis, by Company (2023)
    15.3. Company Profiles
        15.3.1. Taj Pharmaceuticals
            15.3.1.1. Company Overview
            15.3.1.2. Product Portfolio
            15.3.1.3. SWOT Analysis
            15.3.1.4. Financial Overview
            15.3.1.5. Strategic Overview
        15.3.2. IVAX Paper Chemicals
            15.3.2.1. Company Overview
            15.3.2.2. Product Portfolio
            15.3.2.3. SWOT Analysis
            15.3.2.4. Financial Overview
            15.3.2.5. Strategic Overview
        15.3.3. Faran Shimi
            15.3.3.1. Company Overview
            15.3.3.2. Product Portfolio
            15.3.3.3. SWOT Analysis
            15.3.3.4. Financial Overview
            15.3.3.5. Strategic Overview
        15.3.4. AdooQ Bioscience LLC
            15.3.4.1. Company Overview
            15.3.4.2. Product Portfolio
            15.3.4.3. SWOT Analysis
            15.3.4.4. Financial Overview
            15.3.4.5. Strategic Overview
        15.3.5. Sun Pharmaceutical Industries Ltd.
            15.3.5.1. Company Overview
            15.3.5.2. Product Portfolio
            15.3.5.3. SWOT Analysis
            15.3.5.4. Financial Overview
            15.3.5.5. Strategic Overview
        15.3.6. Sanofi S.A.
            15.3.6.1. Company Overview
            15.3.6.2. Product Portfolio
            15.3.6.3. SWOT Analysis
            15.3.6.4. Financial Overview
            15.3.6.5. Strategic Overview
        15.3.7. Freedom Pharmaceuticals
            15.3.7.1. Company Overview
            15.3.7.2. Product Portfolio
            15.3.7.3. SWOT Analysis
            15.3.7.4. Financial Overview
            15.3.7.5. Strategic Overview
        15.3.8. Ascent Scientific
            15.3.8.1. Company Overview
            15.3.8.2. Product Portfolio
            15.3.8.3. SWOT Analysis
            15.3.8.4. Financial Overview
            15.3.8.5. Strategic Overview
        15.3.9. Teva Pharmaceutical Industries Ltd.
            15.3.9.1. Company Overview
            15.3.9.2. Product Portfolio
            15.3.9.3. SWOT Analysis
            15.3.9.4. Financial Overview
            15.3.9.5. Strategic Overview
        15.3.10. Mallinckrodt Pharmaceuticals
            15.3.10.1. Company Overview
            15.3.10.2. Product Portfolio
            15.3.10.3. SWOT Analysis
            15.3.10.4. Financial Overview
            15.3.10.5. Strategic Overview